O3-6-1Interim safety analysis of a phase II trial of modified-FOXFOXIRI plus bevacizumab for RAS mutant mCRC (JACCRO CC-11)
Sunakawa, Yu, Satake, Hironaga, Miyamoto, Yuji, Nakamura, Masato, Nakayama, Hiroshi, Higuchi, Akio, Takeuchi, Masahiro, Fujii, Masashi, Sekikawa, Takashi, Ichikawa, WataruVolume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx697.075
Date:
October, 2017
File:
PDF, 84 KB
2017